Contraindication Ladder - Pharmacodiagnostic Drug Interaction Framework
1 Knadler et al. 2011 — Duloxetine Clinical Pharmacokinetics and Drug Interactions
Full Citation:: Knadler MP, Lobo E, Chappell J, Bergstrom R. Duloxetine: clinical pharmacokinetics and drug interactions. Clinical Pharmacokinetics. 2011;50(5):281–294. (Knadler et al. 2011) DOI:: 10.2165/11539240-000000000-00000 PMID:: 21366359 Study Design:: Comprehensive PK review (Eli Lilly, drug manufacturer) Key Findings::
- Fluvoxamine (CYP1A2 inhibitor) increases duloxetine AUC by 460% (90% CI 359–584) and Cmax by 141% (90% CI 93–200)
- CYP1A2 inhibition produces clinically significant duloxetine exposure increase — listed in prescribing information
- Smoking associated with 30% decrease in duloxetine concentration (CYP1A2 induction)
- Duloxetine is a moderate CYP2D6 inhibitor; duloxetine PK affected by CYP2D6 poor metabolizer status but to a lesser extentConclusion:: Fluvoxamine–duloxetine is a Level 2 (PK catastrophe) contraindicated combination. The ~5× increase in duloxetine exposure carries risk of serotonin syndrome, hepatotoxicity, and exaggerated adverse effects. Documented in FDA labeling. Certainty Assessment::
- *Quality:*: High (Clin Pharmacokinet; manufacturer data)
- *Sample:*: Formal PK interaction study
- *Replication:*: Confirmed in FDA prescribing information and Hanif 2023
- *Score:*: 0.802 Due Bruun et al. 2024 — LDN RCT in Fibromyalgia
Full Citation:: Due Bruun K, Christensen R, Amris K, Vaegter HB, Blichfeldt-Eckhardt MR, Bye-Møller L, Holsgaard-Larsen A, Toft P. Naltrexone 6 mg once daily versus placebo in women with fibromyalgia: a randomised, double-blind, placebo-controlled trial. The Lancet Rheumatology. 2024;6(1):e31–e39. (Due Bruun et al. 2024) DOI:: 10.1016/S2665-9913(23)00278-3 PMID:: 38258677 Study Design:: Single-centre double-blind RCT Sample Size:: n=99 women with fibromyalgia (LDN 6 mg n=49, placebo n=50) Key Findings::
- No significant between-group difference in pain intensity change (−0.34 points, p=0.27, Cohen's d 0.23)
- AEs in 84% LDN vs 86% placebo; discontinuation due to AEs: 8% vs 6%
- Memory signal (highest responder RR 1.67) did not reach significance as a 30% responder category in the secondary-outcome re-analysis [@Nielsen2026LDNFMResponder]Conclusion:: LDN was not superior to placebo for pain in fibromyalgia, and the exploratory memory signal was not significant as a responder category (Nielsen, Vaegter, and Due Bruun 2026). Provides safety characterization relevant to Level 1 — LDN antagonizes μ-opioid receptors, creating a pharmacodynamic contraindication with opioid agonists. Certainty Assessment::
- *Quality:*: High (Lancet Rheumatology)
- *Sample:*: Moderate (n=99)
- *Replication:*: Consistent with Yang 2023 systematic review
- *Score:*: 0.753 Yang et al. 2023 — LDN Systematic Review in Fibromyalgia
Full Citation:: Yang J, Shin KM, Do A, Bierle DM, Abu Dabrh AM, Yin Z, Bauer BA, Mohabbat AB. The Safety and Efficacy of Low-Dose Naltrexone in Patients with Fibromyalgia: A Systematic Review. Journal of Pain Research. 2023;16:1017–1023. (Yang et al. 2023) DOI:: 10.2147/JPR.S395457 PMID:: 36974308 PMCID:: PMC10039621 Study Design:: Systematic review Sample Size:: n=9 studies (1 RCT, 2 case reports, 2 case series, 4 pilot trials) Key Findings::
- LDN effective for symptomatic management of fibromyalgia across heterogeneous studies
- 78% of included studies evaluated safety — no severe adverse events reported
- Evidence level limited; large-sample RCTs neededConclusion:: Provides the most comprehensive safety characterization of LDN. Primary contraindication risk with opioids is pharmacodynamic opposition, not intrinsic LDN toxicity. Certainty Assessment::
- *Quality:*: Medium (J Pain Res; heterogeneous small studies)
- *Sample:*: Aggregated across 9 studies
- *Replication:*: Consistent with Due Bruun 2024 and Patten 2018
- *Score:*: 0.604 Lipworth & Grove 1997 — Partial Beta-Adrenoceptor Agonist Activity
Full Citation:: Lipworth BJ, Grove A. Evaluation of partial beta-adrenoceptor agonist activity. British Journal of Clinical Pharmacology. 1997;43(1):9–14. (Lipworth and Grove 1997) DOI:: 10.1111/j.1365-2125.1997.tb00025.x PMID:: 9056046 Study Design:: Comprehensive review of pharmacological principles Key Findings::
- Partial β-AR agonist exhibits opposite agonist/antagonist activity depending on adrenergic tone
- In presence of exogenous full agonist, β2-AR partial agonist activity expressed as antagonism (e.g., salmeterol attenuating fenoterol responses)
- Reduction of exercise heart rate occurs to a lesser degree with BBs having partial agonist activityConclusion:: Establishes mechanistic basis for Level 1 (Receptor Antagonism). β-blockers + β2-agonists represent direct pharmacodynamic opposition at the receptor level — textbook pharmacology. Certainty Assessment::
- *Quality:*: High (Br J Clin Pharmacol, foundational review)
- *Sample:*: N/A (pharmacological principles)
- *Replication:*: Confirmed in all major pharmacology textbooks
- *Score:*: 0.555 Everly et al. 2004 — Beta-Blocker Underuse in Secondary Prevention of MI
Full Citation:: Everly MJ, Heaton PC, Cluxton RJ Jr. Beta-blocker underuse in secondary prevention of myocardial infarction. Annals of Pharmacotherapy. 2004;38(2):286–293. (Everly, Heaton, and Cluxton 2004) DOI:: 10.1345/aph.1C472 PMID:: 14742768 Study Design:: Systematic literature review Key Findings::
- Absolute BB contraindications: severe bradycardia, sick sinus syndrome, second-/third-degree AV block, severe LV dysfunction, active PVD with rest ischemia, or reactive airway disease requiring airway support
- Cardioselective β-blockers + albuterol can minimize bronchospasm effects
- BB use reduces mortality by 19–48% and reinfarction by up to 28%Conclusion:: Explicit clinical contraindication criteria support Level 1: non-cardioselective β-blockers block β2-mediated bronchodilation, opposing β2-agonist therapy. Certainty Assessment::
- *Quality:*: Medium (Ann Pharmacother)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with all major guidelines
- *Score:*: 0.506 Blockmans et al. 2006 — Methylphenidate in CFS (RCT)
Full Citation:: Blockmans D, Persoons P, Van Houdenhove B, Bobbaers H. Does methylphenidate reduce the symptoms of chronic fatigue syndrome? American Journal of Medicine. 2006;119(2):167.e23–167.e30. (Blockmans et al. 2006) DOI:: 10.1016/j.amjmed.2005.07.047 PMID:: 16443425 Study Design:: Double-blind crossover RCT Sample Size:: n=60 CFS (Fukuda 1994) Key Findings::
- Methylphenidate 2×10 mg/day significantly reduced fatigue vs placebo (CIS: −9.7, p `<` 0.0001; VAS: −1.0, p=0.001)
- Clinical significant effect in only 17% for fatigue, 22% for concentration — 83% non-response
- Did NOT assess PEM as outcomeConclusion:: Stimulants provide short-term benefit in a minority. The 83% non-response may reflect PEM exacerbation from activity masking. Supports Level 4 — stimulants in documented PEM carry risk of energy envelope violation. Certainty Assessment::
- *Quality:*: High (Am J Med, rigorous crossover)
- *Sample:*: Moderate (n=60)
- *Replication:*: Consistent with Van Houdenhove 2010, Eckey 2025
- *Score:*: 0.657 Eckey et al. 2025 — Patient-Reported Treatment Outcomes in ME/CFS and Long COVID
Full Citation:: Eckey M, Li P, Morrison B, Bergquist J, Davis RW, Xiao W. Patient-reported treatment outcomes in ME/CFS and long COVID. Proceedings of the National Academy of Sciences. 2025;122(28):e2426874122. (Eckey et al. 2025) DOI:: 10.1073/pnas.2426874122 PMID:: 40627388 PMCID:: PMC12280984 Study Design:: Large patient survey Sample Size:: n=3,925 (ME/CFS and long COVID) Key Findings::
- 150+ treatments evaluated; 89.7% ME/CFS reported PEM
- POTS-dominant cluster benefited from autonomic modulators; cognitive-dysfunction cluster benefited from CNS stimulants
- Treatment responses correlated between ME/CFS and long COVID (R²=0.68)Conclusion:: Directly supports cluster-specific contraindications. CNS stimulants may be harmful in POTS-dominant ME/CFS (increased HR → PEM exacerbation). Differential cluster response is empirical basis for Level 4 stimulant contraindication. Certainty Assessment::
- *Quality:*: High (PNAS)
- *Sample:*: Large (n=3,925)
- *Replication:*: Consistent with Blockmans 2006
- *Score:*: 0.708 Ponticelli et al. 2023 — Autophagy and Podocytopathy
Full Citation:: Ponticelli C, Moroni G, Reggiani F. Autophagy and podocytopathy. Nephrology Dialysis Transplantation. 2023;38(9):1931–1939. (Ponticelli, Moroni, and Reggiani 2023) DOI:: 10.1093/ndt/gfad024 PMID:: 36708169 Study Design:: Narrative review Key Findings::
- Autophagy regulated by AMPK (activator) and mTOR (inhibitor)
- "Caution is needed with other autophagy activators, such as mTOR inhibitors and metformin, because of potential adverse events"
- No clinical trial with autophagy regulators in podocytopathies conductedConclusion:: Only identified paper warning about combined mTOR inhibitor + metformin use. Supports Level 4: rapamycin + metformin → dual-pathway mTORC1 suppression → potentially excessive autophagy → amplified PEM risk. Certainty Assessment::
- *Quality:*: Medium (NDT)
- *Sample:*: N/A (review)
- *Replication:*: Single cautionary statement; no trial data
- *Score:*: 0.459 Kim & Farrell 2022 — Orthostatic Hypotension: A Practical Approach
Full Citation:: Kim MJ, Farrell J. Orthostatic Hypotension: A Practical Approach. American Family Physician. 2022;105(1):39–49. (Kim and Farrell 2022) PMID:: 35029940 Study Design:: Clinical review Key Findings::
- First-line OH medications: midodrine and droxidopa
- "Although fludrocortisone improves symptoms, it has concerning long-term effects"
- OH associated with up to 50% increase in all-cause mortalityConclusion:: Supports contraindication table: fludrocortisone worsening orthostasis → permanent avoidance. Volume expansion does not address structural venous pooling in connective-tissue-driven OH. Certainty Assessment::
- *Quality:*: Medium (Am Fam Physician)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with Palma 2020
- *Score:*: 0.5510 Palma & Kaufmann 2020 — Management of Orthostatic Hypotension
Full Citation:: Palma JA, Kaufmann H. Management of Orthostatic Hypotension. Continuum (Minneapolis, Minn.). 2020;26(1):154–177. (Palma and Kaufmann 2020) DOI:: 10.1212/CON.0000000000000816 PMID:: 31996627 PMCID:: PMC7339914 Study Design:: Clinical review (AAN Continuum) Key Findings::
- Fludrocortisone associated with renal failure, cardiac failure, increased all-cause hospitalization
- Peripheral denervation → better droxidopa response; central dysfunction → better NE reuptake inhibitor responseConclusion:: Pharmacodiagnostic differentiation of OH type predicts drug response — aligns with ch34 framework. In connective-tissue-driven OH, fludrocortisone may worsen outcomes. Certainty Assessment::
- *Quality:*: High (Continuum — AAN flagship)
- *Sample:*: N/A (review)
- *Replication:*: Consistent with Kim 2022
- *Score:*: 0.6011 Dayal et al. 2025 — Clonidine + Midodrine in SH-OH (Case Report)
Full Citation:: Dayal M, Shah MS, Radfar N, Patel S, Thomas R. Multimodal Management of Supine Hypertension With Orthostatic Hypotension in an Elderly Male Patient With Parkinson’s Disease. Cureus. 2025;17(4):e82394. (Dayal et al. 2025) DOI:: 10.7759/cureus.82394 PMID:: 40385848 PMCID:: PMC12084856 Study Design:: Single case report Key Findings::
- Clonidine + hydralazine at bedtime for SH; midodrine timed around daytime activity for OH
- Temporal separation successfully managed opposing pharmacodynamic goalsConclusion:: Confirms Level 3 (PD Opposition): simultaneous clonidine + midodrine is self-negating, but temporal separation converts opposition into complementarity. Certainty Assessment::
- *Quality:*: Low (Cureus case report, n=1)
- *Sample:*: Single case
- *Replication:*: None
- *Score:*: 0.2512 Amariles et al. 2007 — Clinical Relevance of Drug Interactions
Full Citation:: Amariles P, Giraldo NA, Faus MJ. Clinical relevance of drug interactions. Medicina Clínica. 2007;129(1):27–35. (Amariles, Giraldo, and Faus 2007) DOI:: 10.1157/13106681 PMID:: 17570184 Study Design:: Narrative review [Spanish] Key Findings::
- Proposes DDI classification based on severity and probability of occurrence
- Emphasizes systemic clearance and bioavailability changes as key PK parametersConclusion:: Closest existing framework to DDI severity classification. Uses severity + probability rather than mechanism type — confirming the contraindication ladder’s novel organizational principle. Score:: 0.40
13 Dieu et al. 2019 — High-Risk DDI Prevalence in Paediatric Inpatients
Full Citation:: Dieu LW, Leuppi-Taegtmeyer AB, van den Anker J, Trachsel D, Gotta V. Prevalence of high-risk drug-drug interactions in paediatric inpatients: a retrospective, single-centre cohort analysis. Swiss Medical Weekly. 2019;149:w20103. (Dieu et al. 2019) DOI:: 10.4414/smw.2019.20103 PMID:: 31422575 Study Design:: Retrospective cohort analysis Sample Size:: n=300 paediatric inpatients Key Findings::
- Pharmavista CDSS uses "contraindicated" and "contraindicated by precaution" severity tiers
- Zero cases "contraindicated"; 1.7% "contraindicated by precaution"Conclusion:: Demonstrates existing severity-tiered DDI systems but none organize by mechanism type — confirming the ladder’s novelty. Score:: 0.55